Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 23, 2017
Clinical News

AEVI-001: Ph II/III SAGA data

BioCentury | Feb 1, 2017
Clinical News

AEVI-001: Ph I/II started

BioCentury | Jun 27, 2016
Clinical News

NFC-1: Phase II/III started

BioCentury | May 26, 2016
Targets & Mechanisms

Dissociating ketamine

An NMDA receptor-independent ketamine metabolite might bypass the drug's side effects
BioCentury | Mar 3, 2016
Targets & Mechanisms

Rescue mission

Rescuing synapses in SHANK3 mice
BioCentury | Aug 20, 2012
Emerging Company Profile

Mind-NRG: New neuroprotection

Mind-NRG's neuregulin 1 fragment could treat early stage Parkinson's disease
BioCentury | Aug 13, 2012
Strategy

Spinning Out mGluRs

Merck Serono spins out Prexton to develop mGluR assets for Parkinson's
BioCentury | Jan 5, 2012
Targets & Mechanisms

Fine-tuning mGluRs

Items per page:
1 - 10 of 31